---
document_datetime: 2025-12-02 04:55:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/winrevair.html
document_name: winrevair.html
version: success
processing_time: 0.1077841
conversion_datetime: 2025-12-28 11:22:27.380924
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Winrevair

[RSS](/en/individual-human-medicine.xml/244587)

##### Authorised

This medicine is authorised for use in the European Union

sotatercept Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Winrevair](#news-on)
- [More information on Winrevair](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Winrevair is a medicine used to improve the ability to exercise in adults with pulmonary arterial hypertension (PAH). Patients with PAH have an abnormally high blood pressure in the arteries of the lungs, causing symptoms such as breathlessness and fatigue.

Winrevair is used in combination with other PAH medicines in patients with moderate or marked limitations of physical activity (corresponding to WHO functional class II or III respectively).

PAH is rare, and Winrevair was designated an 'orphan medicine' (a medicine used in rare diseases) on 9 December 2020. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2369) .

Winrevair contains the active substance sotatercept.

Expand section

Collapse section

## How is Winrevair used?

Treatment with Winrevair should be started and supervised by a doctor experienced in the diagnosis and treatment of PAH. The medicine can only be obtained with a prescription.

Winrevair is available as a powder to be mixed with water to make a solution. It is given by injection with a syringe under the skin of the abdomen (belly), upper arm or upper thigh, every 3 weeks. Patients or their caregiver may inject Winrevair themselves after they have been trained to do so.

Before each of the first 5 doses of Winrevair, the doctor will verify that the patient's platelet levels are high enough and haemoglobin levels are not too high. These tests will then be carried out every 3 to 6 months. The doctor may adjust the dose, interrupt or stop treatment if certain side effects occur.

For more information about using Winrevair, see the package leaflet or contact your doctor or pharmacist.

## How does Winrevair work?

The active substance in Winrevair, sotatercept, attaches to and blocks a protein called activin. By doing so, it prevents the thickening and narrowing of small blood vessels in the lungs, thereby lowering blood pressure and making it easier for the heart to pump blood.

## What benefits of Winrevair have been shown in studies?

A main study has shown that Winrevair was more effective than placebo (a dummy treatment) at improving the ability of adults with PAH to exercise. The main measure of effectiveness was the difference in the distance patients could walk in 6 minutes before and after treatment.

In this study, involving 323 patients with PAH, after 24 weeks of treatment, Winrevair given in addition to other PAH medicines improved the distance patients could walk in 6 minutes by around 34 meters, compared with 1 meter in patients who had placebo in place of Winrevair.

## What are the risks associated with Winrevair?

For the full list of side effects and restrictions with Winrevair, see the package leaflet.

The most common side effects with Winrevair (which may affect more than 1 in 10 people) include headache, epistaxis (nosebleed), telangiectasia (small red blood vessels in the skin), diarrhoea, dizziness, rash and thrombocytopenia (low levels of blood platelets).

The most common serious side effects with Winrevair (which may affect up to 1 in 100 people) include thrombocytopenia and epistaxis.

Winrevair must not be given to patients whose platelet levels are consistently low (less than 50 x 10 9 /L) as it may increase the risk of bleeding. Winrevair should also not be used during pregnancy as it may harm the foetus.

## Why is Winrevair authorised in the EU?

In a main study, Winrevair was shown to improve the ability of patients with PAH to exercise. Regarding safety, the side effects of Winrevair were considered manageable. There are limited data about the cardiovascular (affecting the heart or blood circulation) safety of Winrevair and more data are required.

The European Medicines Agency therefore decided that Winrevair's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Winrevair?

The company that markets Winrevair must provide the results of a study assessing the cardiovascular safety of Winrevair.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Winrevair have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Winrevair are continuously monitored. Suspected side effects reported with Winrevair are carefully evaluated and any necessary action taken to protect patients.

## Other information about Winrevair

Winrevair received a marketing authorisation valid throughout the EU on 22 August 2024.

Winrevair : EPAR - Medicine overview

Reference Number: EMA/313481/2024

English (EN) (122.22 KB - PDF)

**First published:** 25/09/2024

[View](/en/documents/overview/winrevair-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-233)

български (BG) (135.61 KB - PDF)

**First published:**

25/09/2024

[View](/bg/documents/overview/winrevair-epar-medicine-overview_bg.pdf)

español (ES) (121.79 KB - PDF)

**First published:**

25/09/2024

[View](/es/documents/overview/winrevair-epar-medicine-overview_es.pdf)

čeština (CS) (142.84 KB - PDF)

**First published:**

25/09/2024

[View](/cs/documents/overview/winrevair-epar-medicine-overview_cs.pdf)

dansk (DA) (121.31 KB - PDF)

**First published:**

25/09/2024

[View](/da/documents/overview/winrevair-epar-medicine-overview_da.pdf)

Deutsch (DE) (123.69 KB - PDF)

**First published:**

25/09/2024

[View](/de/documents/overview/winrevair-epar-medicine-overview_de.pdf)

eesti keel (ET) (118.64 KB - PDF)

**First published:**

25/09/2024

[View](/et/documents/overview/winrevair-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.06 KB - PDF)

**First published:**

25/09/2024

[View](/el/documents/overview/winrevair-epar-medicine-overview_el.pdf)

français (FR) (123.45 KB - PDF)

**First published:**

25/09/2024

[View](/fr/documents/overview/winrevair-epar-medicine-overview_fr.pdf)

hrvatski (HR) (142.66 KB - PDF)

**First published:**

25/09/2024

[View](/hr/documents/overview/winrevair-epar-medicine-overview_hr.pdf)

italiano (IT) (121.83 KB - PDF)

**First published:**

25/09/2024

[View](/it/documents/overview/winrevair-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (150.84 KB - PDF)

**First published:**

25/09/2024

[View](/lv/documents/overview/winrevair-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (143.83 KB - PDF)

**First published:**

25/09/2024

[View](/lt/documents/overview/winrevair-epar-medicine-overview_lt.pdf)

magyar (HU) (143.94 KB - PDF)

**First published:**

25/09/2024

[View](/hu/documents/overview/winrevair-epar-medicine-overview_hu.pdf)

Malti (MT) (145.44 KB - PDF)

**First published:**

25/09/2024

[View](/mt/documents/overview/winrevair-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.24 KB - PDF)

**First published:**

25/09/2024

[View](/nl/documents/overview/winrevair-epar-medicine-overview_nl.pdf)

polski (PL) (145.01 KB - PDF)

**First published:**

25/09/2024

[View](/pl/documents/overview/winrevair-epar-medicine-overview_pl.pdf)

português (PT) (121.91 KB - PDF)

**First published:**

25/09/2024

[View](/pt/documents/overview/winrevair-epar-medicine-overview_pt.pdf)

română (RO) (141.6 KB - PDF)

**First published:**

25/09/2024

[View](/ro/documents/overview/winrevair-epar-medicine-overview_ro.pdf)

slovenčina (SK) (142.93 KB - PDF)

**First published:**

25/09/2024

[View](/sk/documents/overview/winrevair-epar-medicine-overview_sk.pdf)

slovenščina (SL) (143.2 KB - PDF)

**First published:**

25/09/2024

[View](/sl/documents/overview/winrevair-epar-medicine-overview_sl.pdf)

Suomi (FI) (119.57 KB - PDF)

**First published:**

25/09/2024

[View](/fi/documents/overview/winrevair-epar-medicine-overview_fi.pdf)

svenska (SV) (119.94 KB - PDF)

**First published:**

25/09/2024

[View](/sv/documents/overview/winrevair-epar-medicine-overview_sv.pdf)

Winrevair : EPAR - Risk management plan

English (EN) (665.9 KB - PDF)

**First published:** 25/09/2024

[View](/en/documents/rmp/winrevair-epar-risk-management-plan_en.pdf)

## Product information

Winrevair : EPAR - Product information

English (EN) (2.82 MB - PDF)

**First published:** 25/09/2024

**Last updated:** 28/03/2025

[View](/en/documents/product-information/winrevair-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-109)

български (BG) (2.94 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/bg/documents/product-information/winrevair-epar-product-information_bg.pdf)

español (ES) (3.04 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/es/documents/product-information/winrevair-epar-product-information_es.pdf)

čeština (CS) (3.15 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/cs/documents/product-information/winrevair-epar-product-information_cs.pdf)

dansk (DA) (3.1 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/da/documents/product-information/winrevair-epar-product-information_da.pdf)

Deutsch (DE) (3.6 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/de/documents/product-information/winrevair-epar-product-information_de.pdf)

eesti keel (ET) (2.85 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/et/documents/product-information/winrevair-epar-product-information_et.pdf)

ελληνικά (EL) (2.94 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/el/documents/product-information/winrevair-epar-product-information_el.pdf)

français (FR) (3.1 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/fr/documents/product-information/winrevair-epar-product-information_fr.pdf)

hrvatski (HR) (2.83 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/hr/documents/product-information/winrevair-epar-product-information_hr.pdf)

íslenska (IS) (2.86 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/is/documents/product-information/winrevair-epar-product-information_is.pdf)

italiano (IT) (2.98 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/it/documents/product-information/winrevair-epar-product-information_it.pdf)

latviešu valoda (LV) (3.39 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/lv/documents/product-information/winrevair-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.84 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/lt/documents/product-information/winrevair-epar-product-information_lt.pdf)

magyar (HU) (3.14 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/hu/documents/product-information/winrevair-epar-product-information_hu.pdf)

Malti (MT) (3.31 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/mt/documents/product-information/winrevair-epar-product-information_mt.pdf)

Nederlands (NL) (3.63 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/nl/documents/product-information/winrevair-epar-product-information_nl.pdf)

norsk (NO) (2.84 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/no/documents/product-information/winrevair-epar-product-information_no.pdf)

polski (PL) (3.83 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/pl/documents/product-information/winrevair-epar-product-information_pl.pdf)

português (PT) (2.97 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/pt/documents/product-information/winrevair-epar-product-information_pt.pdf)

română (RO) (2.82 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/ro/documents/product-information/winrevair-epar-product-information_ro.pdf)

slovenčina (SK) (2.79 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/sk/documents/product-information/winrevair-epar-product-information_sk.pdf)

slovenščina (SL) (2.7 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/sl/documents/product-information/winrevair-epar-product-information_sl.pdf)

Suomi (FI) (2.95 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/fi/documents/product-information/winrevair-epar-product-information_fi.pdf)

svenska (SV) (3 MB - PDF)

**First published:**

25/09/2024

**Last updated:**

28/03/2025

[View](/sv/documents/product-information/winrevair-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000246288 28/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Winrevair : EPAR - All authorised presentations

English (EN) (22.81 KB - PDF)

**First published:** 25/09/2024

[View](/en/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-395)

български (BG) (25.24 KB - PDF)

**First published:**

25/09/2024

[View](/bg/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.01 KB - PDF)

**First published:**

25/09/2024

[View](/es/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_es.pdf)

čeština (CS) (29.62 KB - PDF)

**First published:**

25/09/2024

[View](/cs/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.14 KB - PDF)

**First published:**

25/09/2024

[View](/da/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (20.91 KB - PDF)

**First published:**

25/09/2024

[View](/de/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (22.95 KB - PDF)

**First published:**

25/09/2024

[View](/et/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (26.06 KB - PDF)

**First published:**

25/09/2024

[View](/el/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_el.pdf)

français (FR) (20.55 KB - PDF)

**First published:**

25/09/2024

[View](/fr/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (27.22 KB - PDF)

**First published:**

25/09/2024

[View](/hr/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.8 KB - PDF)

**First published:**

25/09/2024

[View](/is/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.88 KB - PDF)

**First published:**

25/09/2024

[View](/it/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (28.7 KB - PDF)

**First published:**

25/09/2024

[View](/lv/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (25.39 KB - PDF)

**First published:**

25/09/2024

[View](/lt/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (28.23 KB - PDF)

**First published:**

25/09/2024

[View](/hu/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (23.41 KB - PDF)

**First published:**

25/09/2024

[View](/mt/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.99 KB - PDF)

**First published:**

25/09/2024

[View](/nl/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.89 KB - PDF)

**First published:**

25/09/2024

[View](/no/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.41 KB - PDF)

**First published:**

25/09/2024

[View](/pl/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_pl.pdf)

português (PT) (20.27 KB - PDF)

**First published:**

25/09/2024

[View](/pt/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_pt.pdf)

română (RO) (26.11 KB - PDF)

**First published:**

25/09/2024

[View](/ro/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (29.25 KB - PDF)

**First published:**

25/09/2024

[View](/sk/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.58 KB - PDF)

**First published:**

25/09/2024

[View](/sl/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.61 KB - PDF)

**First published:**

25/09/2024

[View](/fi/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (18.15 KB - PDF)

**First published:**

25/09/2024

[View](/sv/documents/all-authorised-presentations/winrevair-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Winrevair Active substance sotatercept International non-proprietary name (INN) or common name sotatercept Therapeutic area (MeSH) Hypertension, Pulmonary Anatomical therapeutic chemical (ATC) code C02KX06

### Pharmacotherapeutic group

Antihypertensives

### Therapeutic indication

Winrevair, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005647

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Opinion adopted 27/06/2024 Marketing authorisation issued 22/08/2024 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Winrevair : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (124.23 KB - PDF)

**First published:** 28/03/2025

[View](/en/documents/procedural-steps-after/winrevair-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Winrevair : Orphan maintenance assessment report - Initial authorisation

Adopted

Reference Number: EMA/OD/0000157014

English (EN) (987.47 KB - PDF)

**First published:** 25/09/2024

[View](/en/documents/orphan-maintenance-report/winrevair-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Winrevair : EPAR - Public assessment report

Adopted

Reference Number: EMA/330301/2024

English (EN) (8.34 MB - PDF)

**First published:** 25/09/2024

[View](/en/documents/assessment-report/winrevair-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Winrevair

Adopted

Reference Number: EMA/CHMP/289588/2024

English (EN) (156.35 KB - PDF)

**First published:** 28/06/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-winrevair_en.pdf)

#### News on Winrevair

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

[Positive CHMP opinion on first-in-class medicine to treat pulmonary arterial hypertension](/en/news/positive-chmp-opinion-first-class-medicine-treat-pulmonary-arterial-hypertension) 28/06/2024

#### More information on Winrevair

- [EU/3/20/2369 - orphan designation for treatment of pulmonary arterial hypertension](/en/medicines/human/orphan-designations/eu-3-20-2369)

**This page was last updated on** 28/03/2025

## Share this page

[Back to top](#main-content)